ImmunityBio, Inc. (IBRX): Outlook on Core Growth Engines, Emerging Risks, Bull vs Bear Case, and Long-Term Investor Value
A disciplined, evidence-based outlook on ImmunityBio (IBRX), analyzing ANKTIVA’s growth, pipeline optionality, emerging risks, and long-term investor value.
